Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
BUSINESS
Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
Kyowa Kirin said on May 1 that its core operating profit and net profit in the first quarter of 2025 plunged by more than half over a year ago due to a big surge in R&D spending. In January-March, the…
To read the full story
Related Article
- Kyowa Kirin Sees Flat H1 Revenue as Japan Slump Offsets Overseas Gains
August 1, 2025
- Kyowa Kirin Sees Need for Shift of Japan Business: CEO
February 10, 2025
- Kyowa Kirin’s Profit Sags on R&D Spending, but Overseas Biz Fares Well
February 7, 2025
- Kyowa Kirin’s H1 Sales up 16.9% on North American Biz, Strategic Brands
August 5, 2024
- Kyowa Kirin’s FY2023 Sales Up by 2-Digits, Operating Profit Hits Record High
February 8, 2024
- Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
August 4, 2023
- Kyowa Kirin Cuts Net Profit Forecast after Kidney Disease Drug Jettisoned
May 11, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
August 8, 2022
- Kyowa Kirin Books 12.3% Growth in H1 on Global Portfolios, 9.8 Billion Yen FX Gain
August 5, 2022
BUSINESS
- Kisunla Uptake “as Expected” One Year after Approval, Says Lilly Japan Exec
September 19, 2025
- SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026
September 19, 2025
- Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy
September 19, 2025
- Lilly Japan Adds Tablet Formulation for Retevmo
September 19, 2025
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…